Key facts
- It has raised $14.1M; the latest was Later Stage VC in Feb 2025.
- Notable investors include HSG (Hong Kong), Eight Roads, Heda Ventures, Hangzhou Tigermed Consulting Company, Sherpa Healthcare Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for New Trials
- ·The full record, as it builds
Funding rounds
No funding rounds for New Trials are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About New Trials
Provider and developer of a management and monitoring platform designed for clinical trials. The company connects monitoring system, clinical trials matching service, payment/ financials and electronic filing system, enabling users with a comprehensive and easy management platform for clinical trials.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2020
- Website
- newtrials.com.cn/
- Ownership
- Privately Held (backing)
New Trials doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in New Trials shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on New Trials in its N-PORT filings yet. We sweep new filings monthly.